These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 28371836)

  • 1. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
    Nakayamada S; Kubo S; Yoshikawa M; Miyazaki Y; Yunoue N; Iwata S; Miyagawa I; Hirata S; Nakano K; Saito K; Tanaka Y
    Rheumatology (Oxford); 2018 Jan; 57(1):164-174. PubMed ID: 28371836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients.
    Kubo S; Nakayamada S; Yoshikawa M; Miyazaki Y; Sakata K; Nakano K; Hanami K; Iwata S; Miyagawa I; Saito K; Tanaka Y
    Arthritis Rheumatol; 2017 Oct; 69(10):2029-2037. PubMed ID: 28605137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.
    Fukuyo S; Nakayamada S; Iwata S; Kubo S; Saito K; Tanaka Y
    Clin Exp Rheumatol; 2017; 35(4):562-570. PubMed ID: 28516880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy.
    Dulic S; Vásárhelyi Z; Sava F; Berta L; Szalay B; Toldi G; Kovács L; Balog A
    Mediators Inflamm; 2017; 2017():6894374. PubMed ID: 29209104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease.
    Kubo S; Nakayamada S; Zhao J; Yoshikawa M; Miyazaki Y; Nawata A; Hirata S; Nakano K; Saito K; Tanaka Y
    Rheumatology (Oxford); 2018 Mar; 57(3):514-524. PubMed ID: 29253269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanism of action of biological disease--modifying antirheumatic drugs].
    Takahashi N; Ishiguro N
    Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy.
    Iwata S; Nakayamada S; Fukuyo S; Kubo S; Yunoue N; Wang SP; Yoshikawa M; Saito K; Tanaka Y
    Arthritis Rheumatol; 2015 Jan; 67(1):63-73. PubMed ID: 25303149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.
    Picchianti Diamanti A; Rosado MM; Scarsella M; Germano V; Giorda E; Cascioli S; Laganà B; D'Amelio R; Carsetti R
    Clin Exp Immunol; 2014 Sep; 177(3):630-40. PubMed ID: 24773026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changes of intestinal flora and its relevance with memory Tfh and B cells in rheumatoid arthritis patients treated with csDMARDs and csDMARDs + bDMARDs.
    Jiang C; Chi S; Wang F; Zhao C; Yang X; Liu M; Ma B; Chen J; Su C; Duan X
    Immunobiology; 2024 May; 229(3):152798. PubMed ID: 38537424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two populations of circulating PD-1hiCD4 T cells with distinct B cell helping capacity are elevated in early rheumatoid arthritis.
    Fortea-Gordo P; Nuño L; Villalba A; Peiteado D; Monjo I; Sánchez-Mateos P; Puig-Kröger A; Balsa A; Miranda-Carús ME
    Rheumatology (Oxford); 2019 Sep; 58(9):1662-1673. PubMed ID: 31056653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Cytokine Inhibition Modulates Activation and Homing Receptors of Peripheral Memory B Cell Subsets in Rheumatoid Arthritis Patients.
    Mahmood Z; Schmalzing M; Dörner T; Tony HP; Muhammad K
    Front Immunol; 2020; 11():572475. PubMed ID: 33042152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis.
    Aldridge J; Andersson K; Gjertsson I; Hultgård Ekwall AK; Hallström M; van Vollenhoven R; Lundell AC; Rudin A
    Rheumatology (Oxford); 2022 Mar; 61(3):1233-1242. PubMed ID: 34009274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis.
    Liu R; Wu Q; Su D; Che N; Chen H; Geng L; Chen J; Chen W; Li X; Sun L
    Arthritis Res Ther; 2012 Nov; 14(6):R255. PubMed ID: 23176102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.